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Background. Heightened impulsivity has been reported in a subset of people with Parkinson’s disease (PwP) and is considered a
risk factor for the development of impulse control disorders (ICDs). However, at present, there are no recognised biochemical
markers of heightened impulsivity. Objectives. To determine if ceruloplasmin, a serum marker involved in the regulation of iron
and copper homeostasis, is associated with trait impulsivity in PwP. Methods. 'e study measured serum ceruloplasmin and
impulsivity using the Barratt Impulsiveness Scale (BIS-11) in an Australian cohort of 214 PwP. Multivariate general linear models
(GLMs) were used to identify whether higher serum ceruloplasmin levels (>75th percentile) were significantly predictive of BIS-11
scores. Results. Serum ceruloplasmin was higher in females with PD (p< 0.001) and associated with MDS-UPDRS III, Hoehn and
Yahr, and ACE-R scores (p< 0.05). When correcting for covariates, higher serum ceruloplasmin concentrations were associated
with the 2nd order nonplanning impulsivity and with the 1st order self-control and cognitive complexity impulsivity domains.
Conclusions. Higher serum ceruloplasmin levels are independently associated with heightened nonplanning impulsivity in PwP.
'us, serum ceruloplasmin levels may have clinical utility as a marker for heightened impulsivity in PD.
1. Introduction
Impulsive behaviours in people with Parkinson’s disease
(PD) have attracted increasing recognition as a burdensome
neuropsychiatric manifestation of PD. Impulsivity is known
to be a multidimensional construct by nature, likely due to
the complexity of personality constructs [1]. Previously, it
has been demonstrated that PwP exhibits more impulsive
behaviours [2, 3], sometimes referred to as heightened
impulsivity. PwP have also been found to perform poorly on
a range of measures of response inhibition [4, 5], which is an
integral element of impulsivity. Identified in a subset of PwP,
heightened impulsivity represents a risk factor for a variety
of impulse control disorders (ICDs) [2, 6]. A number of
ICDs are thought to be a result of dopaminergic therapies
primarily administered to alleviate motor deficits of PD,
such as dopamine agonists (DAs) [7]. Despite the strong
association between impulsivity and ICDs [2, 6], PwP can
manifest heightened impulsivity even in the absence of an
ICD [8, 9]. 'ese observations represent impulsivity in PwP
on a spectrum of severity and introduce a factor of possible
deterioration through the disease course. PwP will often
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display symptoms of mild cognitive andmotor disinhibition,
ultimately manifesting as a pathologic ICD over time [6].
Whilst several studies have focused on identifying de-
mographic risk factors for the onset of impulsivity and ICDs
in PD [7, 10–13], to date none have investigated serum
markers as predictive or associated factors of impulsivity in
PD. Previous research has suggested a relationship between
PD and serum levels of ceruloplasmin, a multicopper fer-
roxidase enzyme required for cellular efflux of iron from the
central nervous system (CNS) [14], but has not investigated
the relationship with impulsivity. In a study using magnetic
resonance susceptibility-weighted phase imaging, a close
correlation was found between nigral iron content and se-
rum ceruloplasmin levels, with PD subjects with reduced
serum ceruloplasmin levels having significantly higher iron
content than those with normal ceruloplasmin levels and
healthy controls [15, 16].'us, low ceruloplasmin levels may
be associated with increased cerebral iron deposition in PD
although it is not clear if this plays a role in aggravating the
neurodegenerative process. On the contrary, elevated ce-
ruloplasmin levels have been associated with a number of
psychiatric disorders, such as schizophrenia and obsessive-
compulsive disorder (OCD), in which impulsive behaviours
can also occur [17, 18]. Furthermore, symptoms of psychosis
and schizophrenia-like behaviour have also been reported in
selected cases with aceruloplasminemia, a condition char-
acterised by a complete absence of functional ceruloplasmin
[19]. Although it remains unclear whether there is a causal
relationship between levels of ceruloplasmin and psychiatric
disturbances, ceruloplasmin dysfunction is thought to dis-
rupt copper homeostasis [20]. 'is disruption may con-
tribute to dopamine dysregulation, a prominent feature of
these psychiatric disorders and impulsive behaviours [16]. It
is not known whether ceruloplasmin levels have an effect on
progression of cognitive impairment.
In light of the relationship between ceruloplasmin, PD,
and psychiatric disorders associated with dopamine dysre-
gulation, the present study aimed to determine whether
there was an association between serum ceruloplasmin levels
and impulsivity. Impulsivity and impulsive behaviours were
assessed in a cohort of PwP using the Barratt Impulsiveness
Scale 11 (BIS-11), which has been extensively used and
validated in PD [3, 21].
2. Methods
2.1. Participants. A total of 214 people with idiopathic PD
(IPD) were sequentially recruited from three movement
disorders clinics across Australia, as part of the Australian
Parkinson’s Disease Registry (APDR). All were ambulant
and independent with activities of daily living, and none
were known to have any other neurological or psychiatric
disorder. Furthermore, individuals with any active inflam-
matory conditions were able to be determined by standard
blood tests and could be excluded. All participants were
examined and cognitively assessed by a movement disorder
neurologist prior to inclusion in the study for verification of
the diagnosis in accordance with the UK Brain Bank criteria
for IPD [22]. 'e study was approved by the Sir Charles
Gairdner Hospital Human Research and Ethics Committee
(Approval number 2006/073), and written informed consent
was obtained from all participants, in accordance with the
National Health and Medical Research Council of Australia
guidelines.
2.2. Clinical Assessments. Motor symptoms and disease
severity were evaluated in the “ON” state using the MDS-
Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Part III and Hoehn and Yahr Scale [23]. In addition, each
participant was evaluated by a clinical psychologist and
completed a suite of neuropsychological assessments.
Cognition was assessed using the Addenbrooke’s Cognitive
Examination Revised (ACE-R), as previously described
[13, 23], a sensitive test of cognition that can be efficiently
applied in a clinical or research setting [24]. Whether pa-
tients were taking levodopa and/or dopamine agonists was
noted. 'e class of PD medication (carbidopa, Madopar,
Sinemet, Stalevo, entacapone, selegiline, and rasagiline) and
dosage were recorded; all PD medications were then con-
verted to a total levodopa equivalent daily dose (LEDD).
Participants taking D2 dopamine agonists (pramipexole,
rotigotine, or apomorphine) were recorded and considered
as a covariate due to their known association with ICD risk.
2.3.Assessment of Impulsivity. 'eBIS-11 was employed as a
validated self-report questionnaire for screening impulsivity
[21]. 'e BIS-11 consists of 30 questions scored on a four-
point scale, with each item corresponding to one of the three
BIS-11 2nd order domains. Overall BIS-11 scores were
calculated as the sum of these 30 scores (yielding a total score
of 120), with higher scores indicating greater impulsivity.
'e sum of 2nd order BIS-11 attentional, motor, and
nonplanning domains were used to calculate participants’
BIS-11 2nd order domain scores. BIS-11 2nd order atten-
tional scores were scored out of a maximum of 32, and
motor and nonplanning scores were both scored out of a
maximum of 44.
2.4. Blood Collection and Serum Analysis. Fasting blood
samples were collected from participants prior to clinical
assessments. For blood collection, 10ml of whole blood was
taken by median cubital vein venepuncture and stored in a
standard BD EDTA vacutainer® (Becton Dickinson andCompany, Franklin Lakes, N.J.). Serum ceruloplasmin
concentrations were quantified using standardised immu-
noturbidimetric determination assays by State Pathology
services, all of which are registered with the National As-
sociation of Testing Authorities (NATA) for medical testing.
2.5. Data Analysis. Collated data were analysed using IBM-
SPSS (v. 26, IBM Corporation). A significant nominal p
value of ≤0.05 was employed for all statistical tests. Variables
were described using mean and standard deviation (in
brackets, SD) or frequency and percent (in brackets, %), as
appropriate. Normality was assessed using the Shapiro–Wilk
test, with subsequent clinical characteristics analysed using
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independent samples T-Test, Mann–Whitney U, or chi-
square, as appropriate. Ceruloplasmin blood levels were
dichotomised into normal (0–75th percentile) and high
(>75th percentile) groups. Total, 2nd order, and 1st order
BIS-11 scores were used as participant outcome measures.
Wherever appropriate, univariate analysis or Mann-Whit-
ney U-test was performed to identify differences between
ceruloplasmin groups. Cohen’s d ESs were calculated for the
mean differences, with an ES of 0.20 considered small, 0.50
medium, and 0.80 large. Generalised linear models (GLMs)
were conducted in order to analyse the relationship between
serum ceruloplasmin and impulsivity, with correctedmodels
controlling for confounding variables. Total BIS-11 scores
and BIS-11 1st and 2nd order domain scores were con-
sidered separate outcome measures. Residual plots were
examined for all models, and no violations were noted.
3. Results
3.1. Serum Ceruloplasmin Levels and Clinical Characteristics
of the PD Cohort. Clinical assessments, demographic in-
formation, medications, motor, and cognitive function are
presented in Table 1.'e cohort was predominated bymales,
with an average age at assessment of 64.4 years and disease
duration of 8.9 years. At the time of the assessment, 46.3% of
individuals were taking DAs and had an average LEDD of
884.93mg/day. Overall, the cohort exhibited a mean total
motor score (MDS-UPDRS III) of 19.81 (±14.03), an average
of 1.69 (±0.96) on the H&Y scale, and a mean ACE-R of
88.55 (±10.57) (Table 1). Serum ceruloplasmin levels ranged
from 0.10 g/L to 0.49 g/L; females appeared to show a greater
variability of distribution than males. Furthermore, mean
levels were significantly higher in females (0.29± 0.07) than
males (0.24± 0.05; p< 0.001). For subsequent analysis, levels
of ceruloplasmin were dichotomised into normal (0–75th
percentile) and high (>75th percentile) groups.
Mean ceruloplasmin level significantly differed between
groups (0.23± 0.04 vs 0.34± 0.05, p< 0.001). Females pre-
dominated the group with high ceruloplasmin levels, having
a higher mean MDS-UPDRS part III score (23.91± 13.94 vs
18.35± 13.82, p � 0.004), a higher H&Y score (2.04± 0.99 vs
1.57± 0.92, p � 0.002), and a higher ACE-R score
(91.02± 8.23 vs 87.72± 11.14, p � 0.034) (Table 2). Subjects
within the high ceruloplasmin group did not display any
significant differences in age, disease duration, LEDD, or DA
usage.
3.2. Nonplanning Impulsivity Is Associated with High Ceru-
loplasmin Levels. Analyses of relationships between ceru-
loplasmin levels and impulsivity consequently included
covariates identified in Table 3. Patients with high cerulo-
plasmin had significantly higher nonplanning-associated
2nd order impulsivity (p � 0.012) and related 1st order self-
control (p � 0.047) and cognitive complexity (p � 0.028)
items of the BIS-11 (Table 3). In models correcting for
covariates, significant differences remained in 2nd order
nonplanning (padj � 0.003), 1st order cognitive complexity
(padj � 0.020), and 1st order self-control (padj � 0.009).
'us, such differences were independent of gender and other
confounding variables. 'ere were no significant associa-
tions identified between ceruloplasmin levels and the at-
tentional or motor impulsivity domains (Table 3). Total BIS-
11 scores were higher in the high ceruloplasmin group but
did not reach statistical significance.
4. Discussion
Impulsive behaviours are well-recognised in a subset of PwP
and are thought to underlie the development of more
pervasive ICDs [3, 25, 26], which may manifest as patho-
logical gambling and hypersexual and other behaviours [2].
While clinical guidelines and scales have been developed for
the identification and diagnosis of ICDs [27], subclinical
impulsiveness in PwP is much less well-defined and difficult
to identify and categorise. Furthermore, the identification of
heightened impulsivity relies heavily upon self-reporting,
with patients frequently being reluctant to report impulsive
behaviours due to embarrassment and often being unaware
of their existence. As such, identification of a serum marker
would serve as a useful clinical tool in objectively identifying
individuals who are at greater risk of developing ICDs,
particularly those who are being treated with a DA. Here, we
show that high serum ceruloplasmin levels are significantly
related elevated nonplanning impulsivity in PwP, suggesting
that serum ceruloplasmin may serve as a convenient marker
for impulsivity in PD.
Synthesised in the liver, ceruloplasmin is involved in
plasma copper transport [18] and is also thought to be a
ferroxidase enzyme, metabolising highly toxic ferrous iron
into its nontoxic ferric form [14]. Within the CNS, ceru-
loplasmin is expressed on the surface of astrocytes and is
integral in the mobilisation and efflux of iron in normal,
healthy states, preventing the accumulation of toxic ferrous
iron within the brain [14]. Serum ceruloplasmin has been
reported to be reduced in PwP when compared with healthy
control subjects, though evidence is somewhat inconsistent.
'is reduction of ceruloplasmin may reflect impairments in
the ferroxidase activity of ceruloplasmin, which is postulated
to promote an accumulation of toxic iron within the sub-
stantia nigra of PwP, and in turn, accelerate the
Table 1: Summary of demographic and clinical data in PD patient
cohort.
Variable Mean (SD) or n
Gender Male 135Female 79
Patient age (years) 64.44 (9.39)
Disease duration (years) 8.90 (5.93)
Total levodopa (mg/day) 884.93 (616.84)
Dopamine D2 agonist Yes 99No 115
MDS-UPDRS III 19.81 (14.03)
Hoehn and Yahr 1.68 (0.97)
ACE-R 88.55 (10.57)
Mean ceruloplasmin (g/L) 0.26 (0.06)
MDS-UPDRS III, Movement Disorder Society-Unified Parkinson’s Disease
Rating Scale III; ACE-R, Addenbrooke’s Cognitive Examination Revised.
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neurodegenerative process [15, 28–30]. However, other
studies have reported that elevated ceruloplasmin is a feature
commonly associated with inflammatory conditions and
low-grade chronic inflammation, with its synthesis being
induced by inflammatory cytokines and lipopolysaccharide
[31–34]. Such literature aligns with the increasingly accepted
notion that chronic neuroinflammation plays a central role
in the pathophysiology of PD [35, 36].
Increased serum ceruloplasmin has been reported in
patients with psychiatric conditions, notably schizophrenia
and OCD [17–19, 37]. A common presentation within these
neuropsychiatric disorders is impulsivity [38, 39]. Several
studies have revealed that patients with schizophrenia report
higher levels of impulsivity [40], as assessed by the BIS-11
and the stop-signal and delay discounting tasks [38]. Al-
though findings regarding whether impulsivity underlies
OCD are discrepant, some studies have reported that OCD
patients also score higher on self-report measures of im-
pulsivity, including BIS-11 [41–43]. 'erefore, it is not
surprising that increased ceruloplasmin was associated with
higher impulsivity in the present PD cohort.
When the different domains of impulsivity were ana-
lysed for an association with ceruloplasmin levels, GLM
analysis revealed a significant relationship between serum
ceruloplasmin levels and BIS-11 1st and 2nd order domains
pertaining to nonplanning impulsivity. Nonplanning im-
pulsivity refers to a lack of future planning and consideration
for long-term consequences associated with alternate
choices and is reflected in a bias toward the present ori-
entation [44, 45]. In general, elevated nonplanning
impulsivity is associated with blunted reward anticipation
and reduced tolerance for delayed rewards (“increased delay
discounting”) [44, 46]. Subjects displaying nonplanning
impulsivity may favour immediate, often monetary rewards
[44], and as such, nonplanning impulsivity has been asso-
ciated with problem gambling [47]. A similar trend has been
displayed in PwP with pathological gambling, who also score
higher on measures of nonplanning impulsivity than PwP
without pathological gambling [12]. 'erefore, serum ce-
ruloplasmin may serve as a specific marker for nonplanning
impulsivity in PwP and may aid in the identification of
behaviours associated with aberrant reward processing.
Importantly, it may therefore flag harmful behaviours such
as pathological gambling, which is one of the most pervasive
forms of ICD in PwP [7].
Further research is required to elucidate a potential
mechanism that may underlie the relationship between
ceruloplasmin and impulsivity in PD. However, we hy-
pothesis that ceruloplasmin may interfere with physiological
dopamine regulation, in a similar manner as observed in
schizophrenic patients, resulting in the generation of a
hyperdopaminergic state. Indeed, dopamine dysfunction
appears to play a central role in the development of im-
pulsivity in PD [48]. For instance, PET studies in a subset of
PwP exhibiting impulsive-compulsive behaviours have
shown that there is dopamine supersensitivity in mesolimbic
areas, accompanied by an increase in dopamine receptor
density [10]. It must be noted, however, that these neuro-
adaptations could be secondary to the long-term adminis-
tration of dopaminergic medications such as DAs and
Table 2: Univariate analysis of dichotomised ceruloplasmin grouping and clinical measures.
Variable Normal ceruloplasmin (N� 158) High ceruloplasmin (N� 56) Significance (p value; Cohen’s d)
Mean ceruloplasmin (g/L) 0.23 (0.04) 0.34 (0.05) p< 0.001
Gender (male %) 70.3% 42.9% p< 0.001
Patient age (years) 64.01 (9.44) 65.64 (9.21) p � 0.331; d� 0.17
Disease duration (years) 8.92 (6.24) 8.83 (5.02) p � 0.598; d� 0.02
Total levodopa (mg/day) 872.62 (598.17) 950.81 (657.16) p � 0.482; d� 0.12
Dopamine agonist (%) 44.3% 51.8% p � 0.335
MDS-UPDRS III 18.35 (13.82) 23.91 (13.94) p � 0.011; d� 0.40
Hoehn and Yahr 1.57 (0.92) 2.04 (0.99) p � 0.002; d� 0.49
ACE-R 87.72 (11.14) 91.02 (8.23) p � 0.034; d� 0.34
MDS-UPDRS III, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale III; ACE-R, Addenbrooke’s Cognitive Examination Revised.
Table 3: Generalised linear regression models for total BIS-11 and 2nd order and 1st order outcomes in normal and high ceruloplasmin
groups.
Variable Total (n� 214) Low (n� 158) High (n� 56) Näıve comparison Corrected comparison
BIS-11 total score 60.89 (0.63) 60.27 (0.77) 62.63 (1.06) 0.109 0.224
2nd order attentional 15.66 (0.24) 15.59 (0.29) 15.86 (0.43) 0.615 0.670
1st order attentional 10.38 (0.19) 10.35 (0.22) 10.45 (0.33) 0.864 0.427
1st order cognitive instability 5.28 (0.11) 5.23 (0.13) 5.41 (0.19) 0.422 0.209
2nd order nonplanning 23.91 (0.35) 23.40 (0.41) 25.34 (0.62) 0.012 0.003
1st order self-control 12.39 (0.23) 12.12 (0.27) 13.14 (0.45) 0.047 0.020
1st order cognitive complexity 11.52 (0.18) 11.28 (0.22) 12.20 (0.34) 0.028 0.009
2nd order motor 21.29 (0.25) 21.28 (0.29) 21.30 (0.49) 0.991 0.921
1st order motor 13.71 (0.20) 13.69 (0.23) 13.75 (0.39) 0.895 0.946
1st order perseverance 7.58 (0.12) 7.59 (0.14) 7.55 (0.23) 0.767 0.898
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levodopa [10]. Nonetheless, LEDD was not associated with
impulsivity measures in the current cohort, indicating that
ceruloplasmin may be associated with impulsivity inde-
pendently of the effects of dopaminergic medications.
5. Limitations
A number of limitations of the current study must be noted.
Firstly, being a validated measure of the construct of im-
pulsivity, the self-reported nature of the BIS-11 may in-
troduce a degree of bias in the gathered responses due to
patients tending to provide what they consider to be more
socially desirable responses and being less inclined to admit
to impulsive behaviours. In addition, although the absence
of a healthy control group for the neuropsychological studies
may be considered a limitation, it does not detract from the
primary objective and outcome of our study, which was to
determine if there was an association between serum ce-
ruloplasmin levels and measures of impulsivity in a carefully
studied PD cohort. Finally, elevated ceruloplasmin can be a
result of infectious and inflammatory conditions; however,
such information was not collected in this retrospective
cohort as it was deemed to be outside the scope of the aims.
While a limitation, the association between heightened
impulsivity and serum ceruloplasmin still remains, re-
gardless of the cause of the elevated serum ceruloplasmin
levels.
6. Conclusion
To date, this is the first study to explore the relationship
between serum ceruloplasmin levels and impulsivity in PwP.
Our findings in this PD cohort have shown that participants
with high ceruloplasmin levels had higher impulsivity scores
as measured on the BIS-11 scale, specifically in relation to
nonplanning impulsivity, and not in motor or attentional
impulsivity domains. Although females had higher levels of
ceruloplasmin and were predominant in the high cerulo-
plasmin group, the association with impulsivity was inde-
pendent of gender. 'e nature of this association remains
unclear, but it is proposed that changes in iron and copper
homeostasis and dopamine regulation in the basal ganglia
and limbic system may play a part. In light of these findings,
further investigation is warranted in other PD cohorts using
the BIS-11 scale, as well as objective measures of impulsivity
and response inhibition.
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